[go: up one dir, main page]

WO2003057847A3 - METHODS AND MATERIALS FOR MODULATING ENaC-BETA - Google Patents

METHODS AND MATERIALS FOR MODULATING ENaC-BETA Download PDF

Info

Publication number
WO2003057847A3
WO2003057847A3 PCT/US2002/041850 US0241850W WO03057847A3 WO 2003057847 A3 WO2003057847 A3 WO 2003057847A3 US 0241850 W US0241850 W US 0241850W WO 03057847 A3 WO03057847 A3 WO 03057847A3
Authority
WO
WIPO (PCT)
Prior art keywords
beta
methods
materials
enac
modulating
Prior art date
Application number
PCT/US2002/041850
Other languages
French (fr)
Other versions
WO2003057847A2 (en
WO2003057847A8 (en
Inventor
Samuel J Shuster
Ulf N G Arvidsson
Laura S Stone
Hong-Yan Zhang
Lucy Vulchanova Hart
Original Assignee
Algos Therapeutics Inc
Samuel J Shuster
Ulf N G Arvidsson
Laura S Stone
Hong-Yan Zhang
Lucy Vulchanova Hart
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Algos Therapeutics Inc, Samuel J Shuster, Ulf N G Arvidsson, Laura S Stone, Hong-Yan Zhang, Lucy Vulchanova Hart filed Critical Algos Therapeutics Inc
Priority to EP02799996A priority Critical patent/EP1478655A4/en
Priority to US10/500,499 priority patent/US20080027015A1/en
Priority to AU2002364612A priority patent/AU2002364612A1/en
Publication of WO2003057847A2 publication Critical patent/WO2003057847A2/en
Publication of WO2003057847A3 publication Critical patent/WO2003057847A3/en
Publication of WO2003057847A8 publication Critical patent/WO2003057847A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to antisense oligonucleotides, compositions and methods useful for modulating the expression of ENaC-beta. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding ENaC-beta.
PCT/US2002/041850 2001-12-31 2002-12-31 METHODS AND MATERIALS FOR MODULATING ENaC-BETA WO2003057847A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP02799996A EP1478655A4 (en) 2001-12-31 2002-12-31 METHODS AND MATERIALS FOR MODULATING ENaC-BETA
US10/500,499 US20080027015A1 (en) 2002-12-31 2002-12-31 Methods and Materials for Modulating Enac-Beta
AU2002364612A AU2002364612A1 (en) 2001-12-31 2002-12-31 METHODS AND MATERIALS FOR MODULATING ENaC-BETA

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34606901P 2001-12-31 2001-12-31
US60/346,069 2001-12-31

Publications (3)

Publication Number Publication Date
WO2003057847A2 WO2003057847A2 (en) 2003-07-17
WO2003057847A3 true WO2003057847A3 (en) 2003-12-11
WO2003057847A8 WO2003057847A8 (en) 2004-01-15

Family

ID=23357796

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/041850 WO2003057847A2 (en) 2001-12-31 2002-12-31 METHODS AND MATERIALS FOR MODULATING ENaC-BETA

Country Status (3)

Country Link
EP (1) EP1478655A4 (en)
AU (1) AU2002364612A1 (en)
WO (1) WO2003057847A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1190249A2 (en) 1999-06-08 2002-03-27 University Of Iowa Research Foundation Compounds and methods to enhance raav transduction
AR066984A1 (en) 2007-06-15 2009-09-23 Novartis Ag INHIBITION OF THE EXPRESSION OF THE ALFA SUBUNITY OF THE SODIUM EPITELIAL CHANNEL (ENAC) THROUGH ARNI (INTERFERENCE RNA)
EA034363B1 (en) 2010-04-23 2020-01-30 Эрроухед Фармасьютикалс, Инк. PHARMACEUTICAL COMPOSITION FOR INHIBITING BETA-ENaC GENE EXPRESSION AND USE THEREOF
WO2013155406A1 (en) * 2012-04-12 2013-10-17 The Chinese University Of Hong Kong Contragestion and treating inflammation by modulating sodium channel activity in the epithelium
WO2017139381A1 (en) 2016-02-08 2017-08-17 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
EP3426787A1 (en) 2016-03-07 2019-01-16 University of Iowa Research Foundation Aav-mediated expression using a synthetic promoter and enhancer
WO2017205739A1 (en) 2016-05-26 2017-11-30 University Of Iowa Research Foundation cis AND trans REQUIREMENTS FOR TERMINAL RESOLUTION OF HUMAN BOCAVIRUS 1
WO2018132747A1 (en) 2017-01-13 2018-07-19 University Of Iowa Research Foundation Bocaparvovirus small noncoding rna and uses thereof
BR112019023650A2 (en) 2017-07-06 2020-06-02 Arrowhead Pharmaceuticals, Inc. RNAI AGENTS TO INHIBIT ALFA-ENAC EXPRESSION AND METHODS OF USE

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551775B1 (en) * 1997-03-11 2003-04-22 Yale University Method to diagnose and treat pathological conditions resulting from deficient ion transport such as pseudohypoaldosteronism type-1
US20030077773A1 (en) * 2000-12-06 2003-04-24 Brandon Rhonda C. Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551775B1 (en) * 1997-03-11 2003-04-22 Yale University Method to diagnose and treat pathological conditions resulting from deficient ion transport such as pseudohypoaldosteronism type-1
US20030077773A1 (en) * 2000-12-06 2003-04-24 Brandon Rhonda C. Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1478655A4 *

Also Published As

Publication number Publication date
EP1478655A2 (en) 2004-11-24
AU2002364612A8 (en) 2003-07-24
EP1478655A4 (en) 2006-05-10
WO2003057847A2 (en) 2003-07-17
AU2002364612A1 (en) 2003-07-24
WO2003057847A8 (en) 2004-01-15

Similar Documents

Publication Publication Date Title
WO2003011887A3 (en) Antisense modulation of apolipoprotein b expression
WO2002092772A3 (en) Antisense modulation of ptp1b expression
WO2003012057A3 (en) Antisense modulation of serum amyloid a4 expression
WO2003014307A3 (en) Antisense modulation of apolipoprotein(a) expression
WO2003010284A3 (en) Antisense modulation of c-reactive protein expression
WO2003066805A3 (en) Antisense modulation of complement component c3 expression
WO2003046132A3 (en) Antisense modulation of myd88 expression
WO2003022222A3 (en) Antisense modulation of protein kinase r expression
WO2003054154A3 (en) Antisense modulation of mucin 1, transmembrane expression
WO2003057843A8 (en) Methods and materials for modulating trpc4
WO2003008545A3 (en) Antisense modulation of glioma-associated oncogene-2 expression
WO2003053341A3 (en) Antisense modulation of ship-1 expression
WO2001083513A3 (en) Antisense modulation of inhibitor of dna binding-1 expression
WO2002095053A3 (en) Antisense modulation of src-c expression
WO2003057847A8 (en) METHODS AND MATERIALS FOR MODULATING ENaC-BETA
WO2002062951A3 (en) Antisense modulation of casein kinase 2-alpha prime expression
WO2002062954A3 (en) Antisense modulation of casein kinase 2-beta expression
WO2002036810A3 (en) Antisense modulation of talin expression
WO2003052062A3 (en) Antisense modulation of cd36l1 expression
WO2003050244A3 (en) Antisense modulation of g protein-coupled receptor etbr-lp-2 expression
WO2002062818A3 (en) Antisense modulation of casein kinase 2-alpha expression
WO2004050674A3 (en) Methods and materials for modulating trpm2
WO2003031576A3 (en) Antisense modulation of inhibitor-kappa b kinase-gamma expression
WO2003057898A8 (en) Methods and materials for modulating p2x2
WO2003057846A3 (en) Methods and materials for modulating task-3

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 29/2003 UNDER (71) REPLACE "PLYMOUTH,MI 55442 (US)." BY "PLYMOUTH, MN55442 (US)."; UNDER (72, 75) FOR APPLICANTS AND INVENTORS "SHUSTER, SAMUEL, J.", "STONE, LAURA, S." AND "HART, LUCY VULCHANOVA" REPLACE "MI" BY "MN"

WWE Wipo information: entry into national phase

Ref document number: 2002799996

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002799996

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10500499

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 10500499

Country of ref document: US